Nurix Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Nurix Therapeutics, Inc. had return on equity of -49.6%, an operating margin of -340.2%, debt equal to 0.0% of equity and a current ratio of 7.02. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Nurix Therapeutics, Inc.: financial ratios, annual
Fiscal year	2019Nov 2019	2020Nov 2020	2021Nov 2021	2022Nov 2022	2023Nov 2023	2024Nov 2024	2025Nov 2025	LTMAug 2026
Operating margin	−71.5%	−364.7%	−396.3%	−476.0%	−201.4%	−390.5%	−340.2%	41.3%
Net margin	−69.7%	−242.7%	−393.9%	−466.9%	−187.0%	−354.9%	−314.9%	42.0%
Free-cash-flow margin	−3.4%	−26.0%	−302.6%	−445.4%	−116.6%	−333.4%	−313.7%	52.7%
Return on equity	—	−37.2%	−37.1%	−55.8%	−57.1%	−53.2%	−49.6%	39.1%
Return on assets	−49.3%	−19.6%	−26.8%	−40.4%	−37.3%	−37.8%	−39.0%	31.3%
Asset turnover	0.71	0.08	0.07	0.09	0.20	0.11	0.12	0.75
Current ratio	2.44	6.70	4.70	4.51	3.40	6.46	7.02	8.44
Debt to equity	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
R&D as % of revenue	144.7%	373.1%	391.4%	477.6%	245.7%	406.3%	377.4%	47.6%
Capital spending as % of revenue	5.3%	25.5%	19.0%	31.7%	10.9%	17.0%	16.7%	1.4%
Free cash flow ÷ net income	—	—	—	—	—	—	—	125.4%

US$ thousands unless shown otherwise. Fiscal quarters.

Nurix Therapeutics, Inc.: financial ratios, quarterly
Quarter	2024 Q4Nov 2024	2025 Q1Feb 2025	2025 Q2May 2025	2025 Q3Aug 2025	2025 Q4Nov 2025	2026 Q1Feb 2026	2026 Q2May 2026	2026 Q3Aug 2026
Operating margin	−486.7%	−340.7%	−109.7%	<−999%	−612.0%	<−999%	<−999%	83.1%
Net margin	−440.7%	−305.4%	−98.7%	<−999%	−576.1%	<−999%	−990.1%	81.7%
Free-cash-flow margin	−382.8%	−349.9%	−149.4%	−761.3%	−537.4%	<−999%	<−999%	91.3%
Current ratio	6.46	6.26	6.82	5.35	7.02	6.01	6.34	8.44
R&D as % of revenue	506.1%	377.5%	177.3%	>999%	611.5%	>999%	969.3%	11.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · August 31, 2026

What it owns · $1.2bn

Short-term assets $1.1bnLonger-term assets $92m

What it owes, and who funded it · $1.2bn

Short-term liabilities $131mLonger-term liabilities $96mShareholders' equity $968m

Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $131m of liabilities due within a year.
Short-term assets cover long-term liabilities $1.1bn short-term assets against $96m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Nurix Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

11 /100

Weak moat

How hard Nurix Therapeutics's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -34.5% of total assets over 7 years.
Durability 10 / 20

Operating margin has been a median -343.3%; its worst year was -450.5%.
Cash conversion 3 / 20

Free cash flow was positive in 2 of 7 years, at a median -225.0% of revenue.
Discipline 0 / 20

The diluted share count rose 161.0% over five years; stock-based pay has been a median 46.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (16 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: NRIX vs RARE ARWR vs NRIX MIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nurix Therapeutics, Inc.